Fedratinib for the treatment of myelofibrosis: a critical appraisal of clinical trial and “real-world” data
Fedratinib is a predominantly JAK2 inhibitor that has shown efficacy in untreated and ruxolitinib-exposed patients with myelofibrosis (MF). Based o…
